MX2024007768A - Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o. - Google Patents
Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o.Info
- Publication number
- MX2024007768A MX2024007768A MX2024007768A MX2024007768A MX2024007768A MX 2024007768 A MX2024007768 A MX 2024007768A MX 2024007768 A MX2024007768 A MX 2024007768A MX 2024007768 A MX2024007768 A MX 2024007768A MX 2024007768 A MX2024007768 A MX 2024007768A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- treatment
- combination
- reuptake inhibitor
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21216872 | 2021-12-22 | ||
| PCT/EP2022/086965 WO2023118123A1 (en) | 2021-12-22 | 2022-12-20 | Combination of an α2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007768A true MX2024007768A (es) | 2024-07-01 |
Family
ID=80225456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007768A MX2024007768A (es) | 2021-12-22 | 2022-12-20 | Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250049779A1 (https=) |
| EP (1) | EP4452242A1 (https=) |
| JP (1) | JP2025500344A (https=) |
| KR (1) | KR20240124995A (https=) |
| CN (1) | CN118475347A (https=) |
| AU (1) | AU2022418121A1 (https=) |
| CA (1) | CA3256789A1 (https=) |
| IL (1) | IL313646A (https=) |
| MX (1) | MX2024007768A (https=) |
| TW (1) | TW202342033A (https=) |
| WO (1) | WO2023118123A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| HRP20041026A2 (en) | 2002-04-03 | 2005-06-30 | Orion Corporation | Polycyclic compounds as potent alpha2-adrenoceptor antagonists |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| WO2017031319A1 (en) | 2015-08-18 | 2017-02-23 | Massachusetts Institute Of Technology | Noradrenergic drug treatment of obstructive sleep apnea |
| GEAP202416602A (en) | 2017-04-28 | 2024-10-10 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| KR102874891B1 (ko) | 2018-01-30 | 2025-10-21 | 애프니메드, 인코포레이티드 (델라웨어) | 수면 무호흡증을 치료하기 위한 방법 및 조성물 |
| MX2021004883A (es) * | 2018-10-31 | 2021-08-05 | Apnimed Inc Delaware | Metodos y composiciones para tratar apnea del sue?o. |
| PE20221025A1 (es) | 2019-11-06 | 2022-06-16 | Bayer Ag | Inhibidores de los receptores a2c adrenergicos |
-
2022
- 2022-12-20 KR KR1020247023957A patent/KR20240124995A/ko active Pending
- 2022-12-20 CN CN202280085098.8A patent/CN118475347A/zh active Pending
- 2022-12-20 EP EP22840709.4A patent/EP4452242A1/en active Pending
- 2022-12-20 US US18/722,189 patent/US20250049779A1/en active Pending
- 2022-12-20 CA CA3256789A patent/CA3256789A1/en active Pending
- 2022-12-20 MX MX2024007768A patent/MX2024007768A/es unknown
- 2022-12-20 AU AU2022418121A patent/AU2022418121A1/en active Pending
- 2022-12-20 TW TW111148911A patent/TW202342033A/zh unknown
- 2022-12-20 WO PCT/EP2022/086965 patent/WO2023118123A1/en not_active Ceased
- 2022-12-20 IL IL313646A patent/IL313646A/en unknown
- 2022-12-20 JP JP2024537375A patent/JP2025500344A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023118123A1 (en) | 2023-06-29 |
| CN118475347A (zh) | 2024-08-09 |
| US20250049779A1 (en) | 2025-02-13 |
| JP2025500344A (ja) | 2025-01-09 |
| TW202342033A (zh) | 2023-11-01 |
| EP4452242A1 (en) | 2024-10-30 |
| AU2022418121A1 (en) | 2024-07-04 |
| KR20240124995A (ko) | 2024-08-19 |
| IL313646A (en) | 2024-08-01 |
| CA3256789A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502427A1 (en) | Methods and compositions for treating sleep apnea | |
| CR10342A (es) | INHIBIDORES DE LOS CANALES DE IONES TASK-1 y TASK-3 | |
| MX2021003428A (es) | Antagonistas del receptor adrenérgico a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño. | |
| GEP20227366B (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| MX2025004365A (es) | Metodos y composiciones para el tratamiento de la apnea del sue?o | |
| MX2024001713A (es) | Metodos y composiciones para tratar la apnea del sue?o. | |
| MY148955A (en) | Carbamoly-cyclohexanes for treating acute mania | |
| AU2017379247A8 (en) | Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| PL2164492T3 (pl) | Trans-4-{2-[4-(2,3-dichlorofenylo)-piperazyn 1-ylo]-etylo}-N,Ndimetylokarbamoilocykloheksylamina do leczenia schizofrenii | |
| PH12019501458A1 (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| SA522432419B1 (ar) | مثبطات المُسْتقبلة الأدرينِية ألفا سي2 | |
| JOP20230005A1 (ar) | توليفة من مضاد مستقبلة ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) مع حاصرة قناة task1/3 لعلاج انقطاع النفس أثناء النوم | |
| MX2024007768A (es) | Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o. | |
| SA521422114B1 (ar) | عملية لإنتاج أشكال جرعة صيدلانية تحتوي على مثبطات قناة واستخدامها في علاج اضطراب التنفس task-1 و task-3، | |
| Kim et al. | Drug Induced Sleep Endoscopy for Poor-Responder to Uvulopalatopharyngoplasty in Patient with Obstructive Sleep Apnea Patients. | |
| MX2024007764A (es) | Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o. | |
| MX2021005842A (es) | Antagonistas de los adrenoreceptores a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño. | |
| MX2024008522A (es) | Derivados de 2,3-dihidrobenzo[b][1,4]dioxin-2-ilmetil)piperazin-1- ilo para el tratamiento de la apnea del sue?o. | |
| MX2024008523A (es) | Antagonistas del adrenoceptor a2 subtipo c para el tratamiento de la apnea del sue?o. | |
| MX2024007767A (es) | Combinacion de un antagonista del adrenoceptor a2 subtipo c (alfa-2c) con un antagonista del receptor muscarinico para el tratamiento de la apnea del sue?o. | |
| JP2008542443A5 (https=) | ||
| EA201992569A1 (ru) | Способы и композиции для лечения апноэ во сне | |
| Spencer et al. | Does weight loss affect the apnea/hypopnea index? | |
| Dotan et al. | Sleep Induced Dissociation Between Neural Drive And Mechanical Effect Of The Genioglossus In Obstructive Sleep Apnea | |
| Gomez Lopez et al. | Obstructive Sleep Apnea Syndrome Evaluation In A Historical Group Of Bariatric Surgery Patients |